Abstract |
Monitoring the spread of mycobacterium in vivo using biophotonic imaging provides a fast, reliable and sensitive method to evaluate the distribution of the infection. Moreover, this technique allows for a significant reduction in the number of animals required in comparison to conventional anatomopathological studies. Here, we describe for the first time and validate the use of a luciferase-tagged recombinant Mycobacterium bovis BCG for non-invasive bioluminescent imaging of 1) bacterial dissemination in tissues, 2) the efficacy of treatment with anti-mycobacterial drugs and 3) the role of adaptive immune responses in controlling mycobacterial infection in vivo.
|
Authors | Frank Heuts, Berit Carow, Hans Wigzell, Martin E Rottenberg |
Journal | Microbes and infection
(Microbes Infect)
Vol. 11
Issue 14-15
Pg. 1114-21
(Dec 2009)
ISSN: 1769-714X [Electronic] France |
PMID | 19682599
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antitubercular Agents
- Luciferases
- Isoniazid
- Rifampin
|
Topics |
- Animals
- Antitubercular Agents
(therapeutic use)
- Diagnostic Imaging
(methods)
- Disease Models, Animal
- Humans
- Isoniazid
(therapeutic use)
- Luciferases
(genetics, metabolism)
- Luminescent Measurements
- Mice
- Mycobacterium bovis
(genetics, metabolism, pathogenicity)
- Rifampin
(therapeutic use)
- Treatment Outcome
- Tuberculosis
(drug therapy, immunology, microbiology)
|